在经皮冠状动脉干预的慢性冠状动脉综合征患者中,蒂卡格勒勒与克洛皮多格勒相比:系统性审查和元分析
Johann Bill Pinedo-Avila1, Jessica Lucia Valera-Cabrera2, Ana Avalos-Rodríguez3
1Unidad de Cuidados Intensivos de Neurocirugía del Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru.
概括
蒂卡格勒勒和克洛皮多格勒在经过皮肤冠状动脉干预 (PCI) 的慢性冠状动脉综合征 (CCS) 患者中表现出类似的疗效. 提卡格勒勒可能会增加胸痛,但其他安全结果似乎是相似的.
科学领域:
- 心脏病学 心脏病学
- 干预心脏病学 干预心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 目前的指导方针建议用克洛皮多格勒治疗慢性冠状动脉综合征 (CCS) 患者,这些患者经过皮肤冠状动脉干预 (PCI).
- 在这个人群中,蒂卡格勒罗和克洛皮多格雷尔之间的有效性和安全性数据的比较仍然不清楚.
研究的目的:
- 在接受PCI的CCS患者中,与克洛皮多格勒相比,评估蒂卡格勒的疗效和安全性.
- 综合随机对照试验 (RCT) 的证据,以告知临床实践.
主要方法:
- 从PubMed/MEDLINE,EMBASE和CENTRAL数据库获取到2025年2月15日的并行随机对照试验 (RCT) 的系统审查和元分析.
- 包括接受PCI的CCS成年人,比较提卡格雷勒与克洛皮多格雷尔的维持疗法.
- 主要结局包括死亡率,心肌梗塞,生活质量,心力衰竭,中风/过时性缺血性发作 (TIA),再血管化和不良事件,这些事件使用GRADE方法评估证据的确定性.
主要成果:
- 分析了9个涉及3370名患者的RCT.
- 蒂卡格勒罗在心血管死亡率,全因死亡率,心力衰竭,中风/TIA和再血管化方面显示出与克洛皮多格勒尔相似的有效性,尽管对某些结果的证据非常不确定.
- 提卡格勒勒在出血事件中可能具有类似的安全性,但可能会增加胸部疼痛/紧张的风险 (每100名患者中有7.5名).
结论:
- 在接受PCI的CCS患者中,蒂卡格勒对大多数心血管结局的疗效与克洛皮多格勒相似.
- 安全性概况在很大程度上是相似的,与提卡格雷勒相关的胸痛/胸的发病率显著增加.
- 可能需要进一步的研究来澄清有关特定心血管事件和长期结果的不确定性.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.1K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.1K
Coronary Artery Disease V: Interprofessional Care
215
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
215
Acute Coronary Syndrome IV: Interprofessional Care
220
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
220
Peripheral Artery Disease III: Interprofessional Care
252
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
252
Acute Coronary Syndrome III: Diagnostic Studies
219
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
219
Angina IV: Management
241
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
241


